• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceu (NQ: RARE )

    56.96 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 56.96
    Bid (Size) 45.65 (1)
    Ask (Size) 60.00 (1)
    Prev. Close 56.96
    Today's Range 56.96 - 56.96
    52wk Range 31.52 - 58.73
    Shares Outstanding 70,814,462
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ultragenyx to Participate in Investor Conferences in September
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire

    Performance

    YTD
    +18.25%
    +18.25%
    1 Month
    +27.40%
    +27.40%
    3 Month
    +47.37%
    +47.37%
    6 Month
    +10.13%
    +10.13%
    1 Year
    +55.80%
    +55.80%

    More News

    Read More
    Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    3 Genomics Stocks That May Transform Personalized Medicine
    Via InvestorPlace
    Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
    Via Benzinga
    Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
    Via Benzinga
    Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
    Via Benzinga
    Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
    Via Investor's Business Daily
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    Via InvestorPlace
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
    Via Benzinga
    Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.